dovitinib (TKI258) / Novartis, Allarity Therap, Oncoheroes  >>  Phase 2
Welcome,         Profile    Billing    Logout  

37 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dovitinib (TKI258) / Allarity Therap, Oncoheroes
NCT00958971 / 2008-006430-10: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Completed
2
43
Europe, Canada, US, RoW
TKI258, Dovitinib
Novartis Pharmaceuticals
Metastatic Breast Cancer
03/11
03/11
NCT00790426 / 2008-005870-11: Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Completed
2
44
Europe, Canada, US, RoW
TKI258
Novartis Pharmaceuticals
Urothelial Cancer
04/12
04/12
NCT01058434 / 2009-012417-22: Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Completed
2
43
Europe, Canada, US, RoW
TKI258
Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
02/13
02/13
NCT01440959: Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

Checkmark P2 data-ESMO
Sep 2012 - Sep 2012: P2 data-ESMO
Completed
2
30
RoW
dovitinib, A phase II study of TKI258
Asan Medical Center
Gastrointestinal Stromal Tumors
03/13
03/13
ACTRN12612000140853: How does the genetic make-up of renal cell cancer affect the activity of dovitinib?

Completed
2
30
 
Auckland District Health Board (ADHB), Novartis Pharmaceuticals Australia Pty Limited
Renal cell cancer
 
 
NCT01514526 / 2011-002873-47: Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Checkmark ASCO 2013
More
Completed
2
17
Europe
Dovitinib, TKI258
Spanish Oncology Genito-Urinary Group
Adrenocortical Carcinoma
07/13
11/16
NCT01576380: A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Completed
2
11
Japan
TKI258, Dovitinib
Novartis Pharmaceuticals
Adenocarcinoma, Scirrhous, Linitis Plastica, Stomach Neoplasms, Stomach Diseases, Neoplasms by Site, Neoplasms
09/13
09/13
NCT01417143: Dovitinib in Adenoid Cystic Carcinoma

Completed
2
33
RoW
TKI258 (Dovitinib):
Seoul National University Hospital
Adenoid Cystic Carcinoma
12/13
11/14
NCT01524692: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
35
US
Dovitinib (TKI258)
University of Virginia, Novartis Pharmaceuticals
Adenoid Cystic Carcinoma
01/14
12/15
NCT01379534 / 2011-000266-35: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
53
US, Europe, RoW
TKI258, dovitinib
Novartis Pharmaceuticals
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
03/14
03/14
NCT01232296: A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Completed
2
162
Japan, RoW
dovitinib, TKI258, sorafenib
Novartis Pharmaceuticals
Hepatocellular Carcinoma
04/14
04/14
NCT01478373 / 2011-001725-24: Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
39
Europe
Dovitinib (TKI258)
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
07/14
07/14
NCT02065323: A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Withdrawn
2
0
US
Standard ADT, Dovitinib, TKI258
Oscar Goodman, Jr., Comprehensive Cancer Centers of Nevada
Prostate Cancer
08/14
 
NCT01888965: Maintenance Dovitinib for Colorectal and Pancreas Cancer

Terminated
2
9
US
Dovitinib, TKI258
Georgetown University, Novartis
Colorectal Cancer, Pancreas Cancer
08/14
10/14
NCT01964144: An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer

Completed
2
40
RoW
Dovitinib
Yonsei University
Thyroid Cancer
10/14
10/14
NCT01741116: Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Checkmark ESMO 2016
Oct 2016 - Oct 2016: ESMO 2016
Completed
2
44
RoW
TKI258, Dovitinib
Korean Cancer Study Group
Hormone Refractory Prostate Cancer
12/14
10/16
NCT01861197: Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Unknown status
2
27
RoW
Dovitinib
Samsung Medical Center
Squamous NSCLC
01/15
 
NCT01753713: Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
33
US
dovitinib, CHIR-258, receptor tyrosine kinase (RTK) inhibitor TKI258, RTK inhibitor TKI258, TKI258, laboratory biomarker analysis
Manmeet Ahluwalia, MD, National Cancer Institute (NCI), Novartis
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
01/15
09/17
NCT01528345 / 2011-001230-42: Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Checkmark ASCO-2013
May 2013 - May 2013: ASCO-2013
Terminated
2
97
US, Europe, RoW
Dovitinib, TKI258, Fulvestrant, Dovitinib Placebo
Novartis Pharmaceuticals
Metastatic Breast Cancer
04/15
04/15
NCT02108782: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Withdrawn
2
0
NA
dovitinib lactate, CHIR-258, receptor tyrosine kinase inhibitor TKI258, RTK inhibitor TKI258, TKI258, pharmacological study, pharmacological studies, laboratory biomarker analysis
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
05/15
05/15
DILIGENCE-1, NCT01791387: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC

Checkmark ESMO-ECCO-ESTRO 2013
Sep 2013 - Sep 2013: ESMO-ECCO-ESTRO 2013
Unknown status
2
30
RoW
Dovitinib, TKI258
Auckland District Health Board, University of Auckland, New Zealand, IGENZ, Ltd., Auckland, Novartis
Clear Cell Renal Cell Carcinoma
06/15
06/15
DOVE-M, NCT01769547: A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Terminated
2
12
Canada
Dovitinib, TKI258, RTK Inhibitor
Ontario Clinical Oncology Group (OCOG), Novartis Pharmaceuticals
Advanced Malignant Pleural Mesothelioma, MPM
06/15
06/15
DOVE, NCT01678105: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

Completed
2
21
Canada
Dovitinib, TKI258, RTK Inhibitor
Ontario Clinical Oncology Group (OCOG), Novartis Pharmaceuticals
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers, ACC
09/15
09/15
NCT01262027: TKI258 for Metastatic Inflammatory Breast Cancer Patients

Completed
2
22
US
Dovitinib, TKI258
M.D. Anderson Cancer Center, Novartis
Breast Cancer
11/15
11/15
NCT01266070: TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Terminated
2
6
US
Dovitinib, TKI258
M.D. Anderson Cancer Center, Novartis
Von Hippel-Lindau Syndrome
12/15
12/15
SIGNATURE, NCT01831726: Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Completed
2
80
US
Dovitinib (TKI258)
Novartis Pharmaceuticals
Tumor Pathway Activations Inhibited by Dovitinib
12/15
12/15
NCT01676714: Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

Completed
2
10
US
Dovitinib, TK1258
University of California, Davis, Novartis
Non-Small Cell Lung Cancer, Colorectal Cancer
01/16
06/16
NCT01719549: Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Completed
2
19
RoW
Dovitinib, TKI258
Asan Medical Center, Novartis
Gastric Cancer
02/16
11/16
NCT01635907: Dovitinib in Neuroendocrine Tumors

Completed
2
8
US
Dovitinib
Abramson Cancer Center of the University of Pennsylvania
Advanced Metastatic Paraganglioma, Advanced Metastatic Pheochromocytoma, Recurrent Paraganglioma, Recurrent Pheochromocytoma, Unresectable Paraganglioma, Unresectable Pheochromocytoma
03/16
04/16
NCT01732107: Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Terminated
2
13
US
Dovitinib
Noah Hahn, M.D., Novartis Pharmaceuticals, Hoosier Cancer Research Network
Bladder Cancer
03/17
03/17
NCT01994590: Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Terminated
2
4
US
Dovitinib, TKI258, Abiraterone Acetate, Zytiga, Prednisone
M.D. Anderson Cancer Center, Novartis
Prostate Cancer
06/17
06/17
NCT00831792: TKI258 in Castrate Resistant Prostate Cancer

Completed
2
46
US
TK1258, CHIR-258
M.D. Anderson Cancer Center, Novartis
Prostate Cancer
06/17
06/17
NCT00303251: Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Completed
1/2
47
US
TKI258
Novartis Pharmaceuticals
Melanoma
09/09
 
NCT00715182 / 2007-004391-39: A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

Completed
1/2
87
Europe, US, RoW
TKI258
Novartis Pharmaceuticals
Advanced/ Metastatic Renal Cell Cancer
07/12
07/12
NCT01548924: Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Terminated
1/2
13
Europe
Dovitinib, TKI-258, Dovitinib + Paclitaxel, -Taxol, -TKI-258
Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, M.D. Anderson Cancer Center, Hospital Universitari de Bellvitge
Solid Tumors
02/13
08/13
NCT01484041: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Terminated
1/2
12
US
Dovitinib, TKI258, Aromatase Inhibitors, Arimidex, Femara, Aromasin
Georgetown University, Novartis Pharmaceuticals
Breast Cancer
12/15
12/17
NCT01921673: Dovitinib Plus Docetaxel in Gastric Cancer

Completed
1/2
14
RoW
Dovitinib and docetaxel
Asan Medical Center, Novartis Pharmaceuticals
Gastric Cancer
06/16
10/16

Download Options